Search This Blog

Tuesday, January 7, 2025

‘Face BBLs’ can undo horrid Ozempic side effect — and people are spending thousands

 Kya Odom was forced to face a shocking truth after dropping 30 pounds in just over 30 days. 

Her face had deflated.

So to re-plump her mug after shrinking from 155 to 125 pounds, the newly svelte Gen Zer from Columbus, Ohio, opted for a facial fat transfer. 

“I got a face BBL,” Odom, 22, a Hooters waitress turned beauty influencer, told The Post with a laugh, likening her $9,000 cosmetic procedure to the celeb-buzzy Brazilian butt lift. 

And like the BBL surgery, during which baggy bums are made bountiful with fat from other areas of the body, facial fat transfers use liposuctioned chub to reinflate patients’ cheeks for a youthful finish. 

00:01
04:05
Kya Odom spent $9,000 on a facial fat transfer.Courtesy Kya Odom
It’s a minimally invasive treatment (and a more natural alternative to dermal filler) that’s increasing in demand amid the rapid weight loss craze spurred on by Ozempic, Wegovy and Mounjaro.

Researchers from RealSelf, a virtual health care marketplace, determined a 253% surge in interest for facial fat transfers from January 2023 through October 2024, per a December report. 

Mino Clark, CEO of the plastic surgery hub, said the uptick in popularity is directly related to the spike in Ozempic use nationwide. 

“Rapid weight loss from [weight loss meds] is driving higher demand for procedures like facial fat transfers that restore lost volume,” she told The Post. 

It’s all about looking fab, not flabby. 

Experts said that the rise in demand for facial fat transfers is due to the ever-growing popularity of weight loss shots.Christopher Sadowski

Thanks to the current thin-is-in movement, nearly everyone — from A-listers to average joes, and baby boomers to zoomers — is blasting away excess blubber with the help of anti-obesity surgeries and medications like Ozempic, Monjauro and Wegovy. 

Although the societal swing toward slenderizing has triggered a recent decrease in US obesity rates, the pervasiveness of weight loss drugs has left some users looking less than their best. 

The not-so-sexy side effects of the meds, such as the dreaded “Ozempic butt” or limp “Ozempic breasts,” have sent physiques sagging in all the wrong places. 

But it’s “Ozempic face” that really takes the cake. 

On social media, many have alleged superstars such as Jessica Simpson are experiencing “Ozempic face.”Getty Images

Many have alleged that celebs like Jessica Simpson, Sharon Osbourne and Scott Disick, who all have lost weight recently, have lost fullness in their faces, with many speculating it’s because of the jabs.

But rather than re-packing on the pounds, guys and gals are booking appointments to plump up with a doctor’s syringe.

“More people have ‘filler fear’ these days — and that’s especially true in New York,” said Clark, referring to concerns that faux injections might beget unnatural outcomes. “So they’re asking for more subtle results, and seeking out providers who won’t overfill or give them ‘pillow face.’”

Fifth Avenue plastic surgeon Dilip Madnani agreed that the fear of looking haggard is leading the facial fat transfer charge in NYC, where costs for the procedure can range from $5,000 to $7,000. 

“Rapid weight loss results in volume loss in the face,” said Madnani, adding that his office receives between “five to 10 calls” per week for the augmentation. 

“This can lead to hollow cheeks and temples, deeper-set eyes, nasolabial and marionette folds, and sagging skin,” he explained, “[which can make] the face appear older and tired.”

To repair the drooping damage, Madnani typically harvests donor fat from the abdomen or flanks. He then inserts between five to 20 cubic centimeters, or CCs, into the face, depending on the level of volume loss and the patient’s desired look. 

But the expert urged prospective patients to exercise a bit of patience before getting the transfer. 

Madnani suggested that folks on fat-shedding journeys wait until they’ve reached their ideal weight before undergoing a facial fat transfer. Continued weight loss can affect the results, causing the freshly injected fat to shrink or resorb.  

“Facial fat transfer can restore youthful volume,” said the doc, “enhancing beauty and providing a more rejuvenated look, while also improving skin texture and facial contour.”

And it did all of the above for his patient, Sarah. 

“I can look in the mirror now,” the giddy 69-year-old, who chose not to disclose her last name for privacy purposes, told The Post. 

“I can leave the house more quickly as it takes much less for me to be presentable,” continued the New Yorker, who recently went from 215 to 125 pounds with bariatric surgery.

“I attended my high school reunion and had no anxiety about appearance,” Sarah gushed. “My new problem was graciously accepting compliments.”

Odom’s rejuvenated face has, too, received high flattery. 

“My friends at work loved it,” she said.

In addition to her facial fat transfer — for which her surgeon extracted fat from her abdomen and lower chin — Odom also underwent a rhinoplasty surgery on her nose. But she said her colleagues at Hooters barely noticed her new schnoz owing to her renewed glow from the facial fat transfer. 

“It looked like I was Kim Kardashian,” said Odom. “I had full checks, my eyes weren’t hollow.

“I looked alive.”

https://nypost.com/2025/01/07/lifestyle/face-bbls-to-undo-ozempic-face-is-hottest-new-surgery-fad/

AVITA Medical Updates Expected Q4, 2024 Revenue, Provides 2025 Guidance

 For the quarter ended December 31, 2024, AVITA Medical now expects commercial revenue to be approximately $18.4 million, reflecting growth of around 30% over the same period in 2023. Previously provided fourth-quarter guidance was in the range of $22.3 million to $24.3 million. Based on these quarterly results, the company expects full-year 2024 commercial revenue to be approximately $64.3 million, reflecting growth of about 29% over the full year 2023. Previously provided full-year 2024 revenue guidance was in the range of $68.0 million to $70.0 million.

The revision in fourth-quarter guidance is attributable to a combination of factors, with slower-than-expected purchasing activity being the primary driver. Several of the company’s hospital accounts adjusted their inventory levels at the end of their fiscal year, resulting in reduced purchasing during December. While this type of behavior is common at year-end, the extent was more pronounced than we had anticipated, contributing to less revenue in the quarter. We expect normal purchasing activity for these accounts to resume in the first quarter, with deferred purchases from the fourth quarter rolling over.

At the same time, the company continues to scale its business, including the ongoing integration of an expanded sales force and the launch of new products that are expected to drive long-term growth. In 2024, AVITA Medical introduced the first new addition to its portfolio, PermeaDerm®, which is a biosynthetic, transparent wound matrix. In June, the company received FDA approval for its next-generation device, RECELL GO™, followed by FDA approval in December for RECELL GO mini, designed to treat smaller wounds. RECELL GO will continue to drive adoption in both new and existing accounts. Additionally, in December, the FDA cleared Cohealyx™, a new collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. These initiatives, particularly the launches of RECELL GO and Cohealyx, remain central to the company’s growth strategy and broader business potential.

“We grew our revenue in 2024 by approximately 29% over the prior year. We achieved this growth despite lower-than-expected fourth-quarter revenue,” said Jim Corbett, CEO of AVITA Medical. “We remain confident in our long-term growth trajectory as we continue to scale our business. Our strategic investments in our people and new products position us to continue to drive significant growth and sustainable success. We are focused on executing our plan, delivering value to our shareholders, and improving patient outcomes.”

2025 Financial Guidance

  • Commercial revenue for the full-year 2025 is expected to be in the range of $100 to $106 million, reflecting growth of approximately 55% to 65% over the projected full-year 2024 commercial revenue
  • Updating previous guidance, the company now expects to achieve cashflow break-even and GAAP profitability in Q4 2025, instead of Q3 2025

Webcast and Conference Call Information
AVITA Medical plans to report its financial results for the fourth quarter and full year 2024 after the close of the U.S. financial markets on Thursday, February 13, 2025. A conference call and webcast are scheduled for that day at 1:30 p.m. Pacific Time (Friday, February 14, 2024, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its results in further detail.

https://www.globenewswire.com/news-release/2025/01/07/3005867/0/en/AVITA-Medical-Updates-Expected-Fourth-Quarter-and-Full-Year-2024-Revenue-Provides-2025-Financial-Guidance.html

Solid Bio FDA IND Clearance for First-In-Industry Gene Therapy to Treat Friedreich’s Ataxia

 - SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich’s ataxia -

- Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and heart to potentially address the most significant symptoms of the disease -

- Phase 1b clinical trial initiation expected in 2H 2025 -

- Company to hold a conference call tomorrow, January 8, 2025, at 8:30 AM ET -

The Company will host a conference call tomorrow, January 8, 2025, at 8:30 AM ET to discuss the IND clearance for SGT-212 as well as other corporate updates. A live and archived webcast of the call will be available on Solid’s website at www.solidbio.com under the “News & Events” tab in the Investor Relations section, or by clicking here.

Participants may also access the live call by dialing 877-409-2291 (toll-free) or 201-389-0925 (international).

https://www.globenewswire.com/news-release/2025/01/07/3005854/0/en/Solid-Biosciences-Announces-FDA-IND-Clearance-for-First-In-Industry-Dual-Route-of-Administration-Gene-Therapy-to-Treat-Both-Neurologic-and-Cardiac-Manifestations-of-Friedreich-s-At.html

GSK, Pfizer RSV Shots Must Warn About Rare Paralysis Risk

 

GSK Plc and Pfizer Inc.’s vaccines for a common respiratory virus must carry warnings that they may be tied to an increased risk of a rare neurological side effect that can lead to paralysis, the US Food and Drug Administration said.

A study done after the respiratory syncytial virus shots were approved suggests that people given GSK’s Arexvy and Pfizer’s Abrysvo may be at increased risk of Guillain-Barré syndrome for 42 days following immunization, the agency said in a safety communication issued Tuesday.

https://www.bloomberg.com/news/articles/2025-01-07/gsk-pfizer-rsv-shots-to-warn-about-rare-neurological-disorder

US probing Teslas over driverless feature

 The U.S. government is probing Tesla over a driverless feature in its electric vehicles, according to the National Highway Traffic Safety Administration (NHTSA).

The NHTSA cited Tesla’s “Smart Summon” and “Actually Smart Summon” features, which let a user remotely move certain vehicles via phone app. The agency said the features played a part in crashes in which “the user had too little reaction time to avoid a crash, either with the available line of sight or releasing the phone app button, which stops the vehicle’s movement.”

According to the agency, Monday marked the start of the investigation looking into the abilities of Actually Smart Summon in relation to the crash allegations. The agency said it is going to assess factors including “the top speed that a vehicle can attain while Actually Smart Summon is engaged.”

Tesla recently reported its first drop in annual deliveries in at least nine years in spite of a rise in its numbers amid the fourth quarter of 2024. Last week, the company said it delivered 1,789,226 vehicles worldwide last year, slightly lower than 2023’s reported delivery number of 1,808,581 vehicles.

Tesla, which is owned by tech billionaire and President-elect Trump ally Elon Musk, has seen its stock drastically rise in the wake of Trump’s 2024 election win. 

Musk heavily supported Trump in his bid for the presidency, endorsing him following an assassination attempt against the president-elect in July. He also made appearances at rallies for Trump and started America PAC, a pro-Trump super PAC.

The Hill has reached out to Tesla for comment.

https://thehill.com/policy/technology/5072338-tesla-driverless-feature-us-investigation/

'Man who exploded Tesla Cybertruck outside Trump hotel in Las Vegas used generative AI, police say'

The highly decorated soldier who exploded a Tesla Cybertruck outside the Trump hotel in Las Vegas used generative AI including ChatGPT to help plan the attack, Las Vegas police said Tuesday.

A laptop, cellphone and watch are still under review nearly a week after 37-year-old Matthew Livelsberger fatally shot himself just before the truck blew up.

An investigation of Livelsberger’s searches through ChatGPT indicate he was looking for information on explosive targets, the speed at which certain rounds of ammunition would travel and whether fireworks were legal in Arizona.

Kevin McMahill, sheriff of the Las Vegas Metropolitan Police Department, called the use of generative AI a “game-changer” and said the department was sharing information with other law enforcement agencies.

“This is the first incident that I’m aware of on U.S. soil where ChatGPT is utilized to help an individual build a particular device,” he said. “It’s a concerning moment.”

During a roughly half-hour-long news conference, Las Vegas police and federal law enforcement officials unveiled new details about the New Year’s Day explosion.

Among the details law enforcement disclosed: Livelsberger stopped during the drive to Las Vegas to pour racing-grade fuel into the Cybertruck, which then dripped the substance. The vehicle was loaded with 60 pounds (27 kilograms) of pyrotechnic material and officials are still uncertain exactly what detonated the explosion, but said it could have been the flash from the firearm that Livelsberger used to fatally shoot himself.

Livelsberger, an Army Green Beret who deployed twice to Afghanistan and lived in Colorado Springs, Colorado, left notes saying the explosion was a stunt meant to be a “ wake up call ” for the nation’s troubles, officials said last week.

He left cellphone notes saying he needed to “cleanse” his mind “of the brothers I’ve lost and relieve myself of the burden of the lives I took.”

The explosion caused minor injuries to seven people but virtually no damage to the Trump International Hotel. Authorities said that Livelsberger acted alone.

Livelsberger’s letters touched on political grievances, societal problems and domestic and international issues, including the war in Ukraine. He wrote that the U.S. was “terminally ill and headed toward collapse.”

Investigators had been trying to determine if Livelsberger wanted to make a political point, given the Tesla and the hotel bearing the president-elect’s name.

Livelsberger harbored no ill will toward President-elect Donald Trump, law enforcement officials said. In one of the notes he left, he said the country needed to “rally around” him and Tesla CEO Elon Musk.

https://fox59.com/news/national-world/ap-us-news/ap-man-who-exploded-tesla-cybertruck-outside-trump-hotel-in-las-vegas-used-generative-ai-police-say/

Could fandom cause jury nullification in Luigi Mangione trial?

Public sympathy for Luigi Mangione, the man accused of fatally shooting UnitedHealthcare CEO Brian Thompson, could pose the possibility of jury nullification despite the overwhelming evidence mounted against him, some legal experts say. 

Mangione faces multiple counts of murder, including murder as an act of terrorism under federal and state charges in New York and Pennsylvania, after allegedly gunning down Thompson as he was walking to an investor conference in Midtown Manhattan on Dec 4.

The federal charges could carry the possibility of the death penalty, while the maximum sentence for the state charges is life in prison without parole. Prosecutors have said the two cases will proceed on parallel tracks, with the state charges expected to go to trial first.

Since his arrest, Mangione’s online fandom has rapidly grown, with supporters posting sympathetic messages, creating fan accounts and even raising thousands on crowdfunding sites to pay for his legal defense fund.

To these sympathizers, Mangione’s alleged crime symbolizes a rejection of the American health care system. That, coupled with him being easy on the eyes, has turned the suspect into a “modern-day Robin Hood,” former federal prosecutor Neama Rahmani told NewsNation. 

“I have never seen a criminal defendant, much less an accused murderer, receive as much sympathy both on traditional media and social media,” he said. “He is a folk hero of sorts to many.”

Rahmani said there is a “very high possibility” of jury nullification in his case where a sympathetic juror could hold out for Mangione. 

Jury nullification occurs when a jury returns a not guilty verdict even though jurors believe beyond reasonable doubt that the defendant has broken the law. This may happen when jurors disagree with the law or the punishment. 

If that happens, there is a high probability of a mistrial, which happens when jurors aren’t able to reach the same verdict, Rahmani said. A nullifying juror could also convince other jurors to choose an acquittal. 

Defense lawyers will lean in

Mangione’s defense lawyers, like any defense attorneys, will try to utilize any possibility of nullification, former federal prosecutor Joel Cohen said.

“That’s their job,” he said, to find those nullifiers and keep them on the jury, and in this case, there is a real possibility of it happening. 

With the seemingly overwhelming evidence against Mangione, jury nullification could be what gets him acquitted or results in a mistrial, so the defense will lean into this, he said.  

In most cases, people come in with some sort of bias, and even when they say they are capable of putting that aside for the case, it still manages to creep in, Cohen said. While a juror does not have the right to nullify, once they are seated, they have the power to do it, he added.

“Most jurors who have that nullifying feeling are not going to be honest about it most of the time, so it’s really hard to get into their heart and soul to find out what they’re really thinking and what the reason is for wanting to be on the jury,” he added.

That’s where judges and prosecutors really need to step up and do their best to weed it out, he said. 

Evidence will prevail

Not all legal experts see nullification as a potential threat.

“I think it’s very unlikely that a case like this is going to confront something like jury nullification,” Gregory Germain, a professor at Syracuse University College of Law, said. “Most of us hate insurance companies and have had difficult experiences dealing with insurance companies, but that doesn’t mean we think people should be going around murdering insurance executives in the street.” 

Germain noted that it’s unlikely potential nullifiers will be able to hide that level of bias during the jury selection process. He adds that while Mangione does have a large fanbase, most “people who want to live in a civilized society are not going to find him to be an appealing defendant.”

The mountain of evidence that appears to be against him will be too great for jurors to fling aside, he said.

“It just sounds like such an overwhelmingly strong case of murder that I just would be shocked if a jury came back with a not guilty verdict,” Germain added.

Larger dangers of jury nullification

Jury nullification in the Mangione case could set a dangerous precedent that undermines the legal system, Rahmani said.

“If we can’t convict murderers who are caught in broad daylight in Manhattan because of the nature of the victim, it’s going to be a problem,” Rahmani said. “Our legal system is based on fair, impartial juries, so anything that threatens that will pose issues.”

The sentiment is shared by Cohen, who said there are several “dangers” of jury nullification, especially if it was done through deception during the jury selection process. 

If people think they will get off the hook because a victim is unsympathetic, that may lead to similar attacks, he said. In the Mangione case, it’s even more concerning because this appears to be a planned attack. 

https://thehill.com/regulation/court-battles/5070319-luigi-mangione-unitedhealthcare-shooting-jury-nullification/